Two Distinct Clinical Patterns of Ibrutinib-to-Venetoclax Transition in Relapsed Chronic Lymphocytic Leukemia Patients - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35448201/
Patients with chronic lymphocytic leukemia (CLL) relapsing on ibrutinib are often treated with the Bcl-2 inhibitor venetoclax. However, the transition from one agent to another poses some clinical challenges due...
Conclusion: A high burden of BTK and PLCG2 mutations was found only in patients with the favorable transition pattern, suggesting that removing BTK inhibition might be particularly harmful if CLL cells are progressing through mechanisms external to the BTK axis.
Cardiotoxicity of BTK inhibitors: ibrutinib and beyond
Source : https://www.tandfonline.com/doi/abs/10.1080/17474086.2022.2067526?journalCode=ierr20
ABSTRACT The development of Bruton s Tyrosine Kinase (BTK) inhibitors has transformed the treatment of B-cell malignancies and other non-malignant conditions. Management of the unique cardiotoxic profile of these agents...
Expert Opinion: The newer BTK inhibitor acalabrutinib represents a new standard of care in front-line chronic lymphocytic leukemia (CLL) given the results of the ELEVATE-RR trial demonstrating comparable efficacy and a more favorable toxicity profile especially with regard to cardiac adverse events as compared to ibrutinib. Often not recognized...
Updates in hairy cell leukemia (HCL) and variant-type HCL (HCL-V): rationale for targeted treatments with a focus on ibrutinib - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35450208/
Bruton's tyrosine kinase (BTK) inhibitors (BTKi) in hairy cell leukemia (HCL) and variant-type HCL The treatment of hairy cell leukemia (HCL) has changed significantly in recent years. In the first-line...
Conclusion: Preclinical and recent clinical data showed an efficacy of ibrutinib, a BTK inhibitor (BTKi), in HCL and HCL-V. These promising results joined those of other emerging drugs like BRAF or MEK inhibitors and anti-CD22 immunotoxins.
Ibrutinib in the Treatment of Solid Tumors: Current State of Knowledge and Future Directions - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35456016/
Bruton's Tyrosine Kinase (BTK) is considered crucial in the activation and survival of both physiological and malignant B-cells. In recent years, ibrutinib, an oral BTK inhibitor, became a breakthrough therapy...
Conclusion: This review aims to describe the milestones in translating BTK inhibitors to solid tumors in order to understand the future potential of this agent better.
Combining BTK inhibitors with BCL2 inhibitors for treating chronic lymphocytic leukemia and mantle cell lymphoma - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35379357/
The advent of BTK inhibitors has changed the treatment of patients with chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). The first-in-class BTK inhibitor ibrutinib has shown remarkable therapeutic...
Conclusion/Relevance: In this review, by focusing on CLL and MCL, we discussed the rationale for the combinational use and summarized the current data on the combinations of BTK inhibitors and venetoclax in patients with CLL and MCL.
-
Leukemia and Lymphoma Connect3yrThanks for your input, [~Connie--Batlevi--leec@ ] ! Would anybody else consider using this combination? What results or further support would you like to see from Phase 3 trials?
-
Connie Batlevi3yrBOVEN (obin, ven, zanubrutinib) is an excellent demonstration of BCL2, BTK and CD20 therapy. After median surveillance after treatment of 15·8 months, 94% of patients had undetectable MRD.